[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519397":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":40,"centralContacts":63,"locations":70,"responsibleParty":83,"collaborators":10,"id":85,"slug":10,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":10,"enrollmentInfo":94,"targetDuration":97,"studyType":98,"phases":10,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":73,"whyStopped":10,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"iOMEDICO AG","INDUSTRY",[8,14,18,22,26,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Chronic Lymphocytic Leukemia (CLL)",null,"Patients with CLL receiving systemic treatment (physician's choice)",[13],"Other: Routine care as per site standard.",{"label":15,"type":10,"description":16,"interventionNames":17},"Diffuse Large B-cell Lymphoma (DLBCL)","Patients with DLBCL receiving systemic treatment (physician's choice)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Follicular Lymphoma (FL)","Patients with FL receiving systemic treatment (physician's choice)",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Mantle Cell Lymphoma (MCL)","Patients with MCL receiving systemic treatment (physician's choice)",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Marginal Zone Lymphoma (MZL)","Patients with MZL receiving systemic treatment (physician's choice)",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Waldenström's macroglobulinemia (WM)","Patients with WM receiving systemic treatment (physician's choice)",[13],[35],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":10},"OTHER","Routine care as per site standard.","Physician's choice according to patient's needs.",[9,15,19,23,27,31],[41,45,48,51,54,57,60],{"name":42,"affiliation":43,"role":44},"Rainer Claus, Prof. Dr.","Universitätsklinikum Augsburg, Germany","STUDY_CHAIR",{"name":46,"affiliation":47,"role":44},"Tobias Dechow","Studienzentrum Onkologie Ravensburg, Germany",{"name":49,"affiliation":50,"role":44},"Paul Graf La Rosée, Prof. Dr.","Schwarzwald-Baar Klinikum, Germany",{"name":52,"affiliation":53,"role":44},"Jens Kisro, Dr.","Lübecker Onkologische Schwerpunktpraxis, Germany",{"name":55,"affiliation":56,"role":44},"Patrick Marschner, Dr.","Praxis für Interdisziplinäre Hämatologie und Onkologie, Freiburg, Germany",{"name":58,"affiliation":59,"role":44},"Ingo Tamm, PD Dr.","Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany",{"name":61,"affiliation":62,"role":44},"Robert Zeiser, Prof. Dr.","Universitätsklinikum Freiburg, Germany",[64],{"name":65,"role":66,"phone":67,"phoneExt":68,"email":69},"Martina Jänicke, Dr.","CONTACT","+4976115242","0","rubin@iomedico.com",[71],{"facility":72,"status":73,"city":74,"state":10,"zip":10,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":10},"Praxis für Interdisziplinäre Hämatologie und Onkologie","RECRUITING","Freiburg im Breisgau","Germany","DE",{"type":78,"coordinates":79},"Point",[80,81],7.85222,47.9959,{"lat":81,"lon":80},{"type":84,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100519397",false,"NCT06043011","Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms","Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms","RUBIN","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Confirmed diagnosis of the respective NHL\n* If patient is alive: signed written informed consent\n\n  * For patients participating in the PRO survey: IC prior to or at day of start of respective line of treatment.\n  * For patients not participating in the PRO survey: IC latest eight weeks after start of respective line of treatment.\n\nExclusion Criteria:\n\n* No systemic therapy for respective lymphoid malignancy.","ALL","18 Years",{"count":95,"type":96},2950,"ESTIMATED","5 Years","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.",[9,15,19,23,27,101],"Waldenström's Macroglobulinemia (WM)",[103],"non-Hodgkin lymphoma (NHL)","2026-01-26",{"date":106,"type":107},"2026-01-28","ACTUAL",{"date":109,"type":107},"2023-09-27",{"date":111,"type":96},"2033-12",{"name":5,"class":6},1]